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Abstract 
Individual response to xenobiotic exposures depends on the 
dynamics of xenobiotic metabolism and the circadian clock 
system, among other factors. Since these systems are closely 
related, polymorphisms in their key genes may have an 
impact on how carcinogenic compounds are metabolized, 
and therefore on the risk of tumor development. Whereas 
the mammary gland is exposed to agents that damage DNA, 
it was considered of high interest to study xenobiotic 
metabolizing genes (XMG) and clock genes in this tissue. 
Our aim was to analyze genotype and allele frequencies of 
polymorphisms in the XMG N-acetyl transferase 2 (NAT2) 
and glutathione S-transferase T1 (GSTT1), and in the clock 
genes period 3 (PER3) and CLOCK in human breast tumor 
samples. As well, it was if these polymorphisms were in 
linkage disequilibrium. 65 samples were genotyped for 
polymorphisms in GSTT1 (null), NAT2 (C481T, G590A and 
G857A), CLOCK (T3111C) and PER3 (length polymorphism), 
by PCR and PCR-RFLP. For GSTT1, 20% of the samples 
showed total absence of the gene. When NAT2 genotypes 
were grouped by their associated acetylator phenotype, 5% 
of rapid, 49% of intermediate and 46% of slow acetylator 
phenotypes were indicated. Allele frequencies for CLOCK 
were T=0.78 and C=0.22; for PER3, they were 0.66 for the 4-
repeats allele and 0.34 for the 5-repeats allele. Linkage 
disequilibrium test indicated evidence of strong linkage 
between NAT2 and CLOCK (χ2=13.076; p=0.005). With 
regard to allele and genotype frequencies, our results are in 
agreement with those reported for similar populations. The 
evidence of linkage disequilibrium in our breast cancer 
samples is interesting and requires further investigation. 
This work constitutes a first approximation to a combined 
study of polymorphisms in XMG and clock genes in breast 
cancer Argentinian patients. Future studies will attempt to 
address the role of these and other polymorphisms in cancer 
risk, prognosis and response to treatment. 
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Introduction 
The way individuals respond to drugs, in terms of 
toxicity and treatment efficacy, and xenobiotics in 
general is highly diverse. Nowadays, it is well 
recognized that inherent differences in xenobiotic 
metabolism may have a considerable influence on the 
toxicity of these compounds, and their therapeutic 
efficacy in the case of drugs (Evans and Relling 1999). 
However, genetic differences in the metabolizing 
system are not the only cause of variation in the effects 
of xenobiotics. Numerous studies have demonstrated 
changes over 24 hours in all the processes determining 
the availability of drugs (Bruguerolle 1998). Therefore, 
the way the circadian clock works is essential to define 
the individual response to xenobiotics exposure. 
Xenobiotic metabolizing enzymes (XMEs), coded by a 
large family of xenobiotic metabolizing genes (XMG), 
convert endogenous and exogenous compounds into 
derivatives that can be removed more easily from the 
body. However, these same enzymes can convert 
certain metabolites to carcinogens highly toxic and 
reactive. The existence of pharmacogenetic polymorphisms 
in XMG has been known for decades, usually 
associated with aberrations in the expression or 
enzyme function (Kalow 1962; Kalow 1992). As a 
consequence, elevated risks of some types of cancers 
have been associated with certain polymorphisms that 
cause an impaired ability to inactivate mutagenic 
molecules (Nebert 1988; W. W. Weber and Nebert 1990; 
Gonzalez and Nebert 1990).  
N-acetyl transferase 2 (NAT2) and glutathione S-
transferase T1 (GSTT1) are phase II XME, reported to 
be polymorphic. GSTT1 is involved in detoxifying 
carcinogens and reactive intermediates, and plays an 
important role in protecting against oxidative stress. A 
deletion of both copies of the GSTT1 gene results in 
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the complete loss of mRNA and protein product. 
Individuals lacking GSTT1 genes have a higher 
incidence of bladder, breast, lung and colorectal cancer 
(Jancova, Anzenbacher, and Anzenbacherova 2010). 
NAT2 is involved in the biotransformation of aromatic 
amines and hydrazines. Several missense and silent 
substitutions have been described in the coding exon 
of NAT2, responsible for the acetylator phenotype. 
NAT2 *4 allele is considered as the wild-type due to 
the absence of such mutations, and represents the 
rapid acetylator phenotype. NAT2*5, *6 and *7, among 
others, define alleles associated with slow acetylation. 
The different acetylator phenotypes are predisposing 
factors for the sensitivity of individuals to toxicity; in 
fact, NAT2 slow acetylation genotype has been 
associated with risk of developing non-Hodgkin 
lymphoma, lung, colon, liver and bladder cancer 
(Agúndez 2008).  
The metabolism of xenobiotics is influenced by the 
circadian clock, as well as the rest of the physiological 
functions. The central clock is located in the 
suprachiasmatic nuclei of the hypothalamus, and 
peripheral clocks are located in many tissues (Schibler, 
Ripperger, and Brown 2003; Levi and Schibler 2007). 
The genes that control circadian functioning are well 
conserved among mammals, and include CLOCK, 
BMAL1, PER and CRY families and a large array of 
complementary genes (Sehgal 2004).  
A small set of clock-controlled genes (CCG) is 
expressed in multiple organs, encoding key regulators 
of cell cycle progression and apoptosis (Fu and Lee 
2003; Zhao and Lee 2010). Based on this evidence, Fu 
and Lee (Fu and Lee 2003) suggested that the circadian 
clock may function as tumor suppressor. In addition, 
“the circadian genes hypothesis” has also been 
proposed (Hoffman et al. 2009), which suggests that 
genetic variants of clock genes can affect individual 
susceptibility to cancer, given the results of 
epidemiological studies (Zhu et al. 2005; Zhu et al. 
2006; Zhu et al. 2008; Hoffman et al. 2010; Dai et al. 
2011; Chu et al. 2008).  
CLOCK is a transcription factor with an essential role 
in the feedback loop involved in the circadian clock 
operation. Single nucleotide polymorphism T3111C, 
located in the 3'-UTR region of CLOCK could affect 
the phenotype by disrupting microRNA binding sites. 
Furthermore, it seems to affect both stability and half-
life of the mRNA (Mignone et al. 2002). A correlation 
between polymorphisms in CLOCK and breast cancer 
risk has been reported (Hoffman et al. 2010), with 
apparent effect modification by estrogen receptor or 
progesterone receptor status. Period3 (PER3) belongs 
to the Period gene family and is another central 
component in the clockwork mechanism. PER3 gene 
has a length polymorphism (VNTR, variable number 
tandem repeats), consisting of 4 or 5 copies of a 54 bp 
repeated sequence.  As a result, a protein with an indel 
of 18 amino acids is obtained. The least number of 
amino acids that are phosphorylation substrates, in the 
short variant, may have a functional impact on the 
phosphorylation-dependent activity, such as on 
stability and translocation of PER3 to the nucleus. 
Genotypes 4/5 and 5/5 in this gene have been 
associated with an increase in breast cancer risk 
among premenopausal women (Zhu et al. 2005).  
It is noteworthy that transcription factors CAR, PPARa, 
AhR/Arnt and PARbZip are regulated by the clock, 
generating circadian expression patterns in many 
XMG, which changes the way that xenobiotics are 
metabolized over 24 hours (Lim et al. 2006; Gachon 
and Firsov 2011). Given the close relationship between 
the circadian clock and metabolic processes, it is 
possible that polymorphisms in key genes of both 
systems have an impact on how carcinogenic 
compounds are metabolized, and therefore on the risk 
of tumor development. For Argentina, breast cancer is 
the most common cancer in women, a feature that is 
repeated throughout the world (GLOBOCAN - IARC 
2008). Whereas the mammary gland is exposed to 
agents that damage DNA, it was considered 
interesting to study XMG and clock genes in this tissue. 
Our work aim at analyzing the genotype and allele 
frequencies of polymorphisms in the XMG NAT2 and 
GSTT1, and in the clock genes CLOCK and PER3 in 
human breast tumor samples. It was also investigated 
if these polymorphisms were in linkage 
disequilibrium, in order to get information about 
possible combinations of alleles at different loci that 
could be related to breast cancer. Currently, there is no 
conclusive evidence that associate the polymorphisms 
with increased/decreased risk of disease. Moreover, 
allelic frequencies can differ between populations. 
This study is one of the first to evaluate the allelic and 
genotypic frequencies of these genes, for an 
Argentinian population of women with breast cancer, 
constituting a basis for future association studies. 
Materials and Methods  
Samples 
This study included 65 DNA samples from female 
patients with breast cancer, between 30 and 85 years 
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old, who were previously analyzed for NAT2, GSTT1 
and GSTM1 polymorphisms (Pavicic, Laguens, and 
Richard 2009). All patients were Argentinian citizens. 
Briefly, samples were obtained from a Clinic Centre in 
La Plata City, Buenos Aires. Each patient signed an 
informed consent, approved by the Ethics Clinic 
Committee. Breast tumor tissue samples were 
obtained from biopsies or surgery, between 1997 and 
2004, prior to radio- and/or chemotherapy. Those 
tissues that showed 85% or more of abnormal cellular 
composition according to routine histopathological 
techniques, were considered tumoral. DNA extraction 
was performed as previously described (Pavicic, 
Laguens, and Richard 2009). 
XMG Analysis 
Polymorphisms in the genes NAT2 and GSTT1 of the 
phase II of detoxification system were detected by 
PCR and PCR-RFLP. Most of the samples were already 
genotyped in previous studies of our group (Pavicic, 
Laguens, and Richard 2009); here the reactions in 
those samples were employed that could not be 
processed before because of lack of DNA or problems 
with the techniques. As a result, this study included a 
different set of samples that those previously published. 
All the genotypes (published and unpublished) were 
included in the current combined analysis of genetic 
polymorphisms in XMG and clock genes. 
1)  GSTT1 Gene 
GSTT1 gene deficiency resulted from the deletion 
of the locus (null allele). The detection was 
performed by duplex PCR with CYP1A1 as an 
internal positive control, in a final volume of 15 μl 
with 1X buffer, 50 ng DNA, 1.5 mM MgCl2, 200 μM 
dNTPs, 0.25 μM and 0.12 μM primers for       
GSTT1 and CYP1A1, respectively, 0.45 U Taq 
Platinum Polymerase (Invitrogen, Life Technologies), 
and H2O up to 15 μl. GSTT1 forward primer                 
5'-TCCTTACTGCTCACAGTCCT-3' and GSTT1 
reverse primer 5'-TCACCGGATCATGGCCAGCA 
-3' were applied for amplification of                        
490 bp fragment; CYP1A1 forward primer 5'-
GGACTGCTGCCATCTCAGCTT-3' and CYP1A1 
reverse primer 5'-CAGCATCTGGAATTGGTGCTC 
-3', were used to amplify the internal control with a 
product of 312 bp. PCR reactions were carried out 
using an initial denaturation at 94°C for 5 min, 
followed by 35 cycles of 1 min at 94°C, 1 min at 
58°C and 1 min at 72°C, with a final extension at 
72°C for 5 min. Verification of PCR products, and 
subsequent identification of genotype, were 
performed using 2% agarose gels stained with 
GelRed (Biotium Inc., CA, USA.) 
2)  NAT2 Gene 
By PCR-RFLP, we studied the polymorphisms 
C481T (dbSNP ID: rs1799929), G590A (dbSNP ID: 
rs1799930) and G857A (dbSNP ID: rs1799931). The 
alleles defined by these substitutions, called *5, *6 
and *7, respectively, are associated with slow 
acetylator phenotypes (University of Louisville 
2012).  
We amplified a 578 bp fragment, in a final volume 
of 20 μl, with 1X buffer, 50 ng DNA, 1.5 mM MgCl2, 
200 μM dNTPs, 0.25 μM of each primer, 0.6 U of 
Taq Platinum Polymerase and H2O up to 20 μl. 
PCR parameters were as follows: an initial 
denaturation at 94°C for 5 min, followed by 30 
cycles of 1 min at 94°C, 1 min of annealing at 58°C 
and 1 min of extension at 72°C, ending with an 
extension of 5 min at 72°C. Primers used were: 
forward 5'-GATTCTATAGAGAGGAGCAC-3' and 
reverse 5'-GGATCCAGCTCCCAGTGATG-3'. After 
checking amplification in 2% agarose gels, we 
proceeded to digest 5 μl of PCR product in a final 
volume of 15 μl, using 5U of restriction enzyme in 
an appropriate buffer for KpnI (C481T) and TaqI 
(G590A). In the case of BamHI (G857A), 2.5 μl of 
PCR were digested in a final volume of 10 μl, also 
using 5U of enzyme. Incubation time was 5 hours 
at 37°C for KpnI and BamHI, and at 65°C for TaqI. 
Digestion products were visualized independently, 
in 4% low melting point agarose gels, stained with 
GelRed (Biotium Inc., CA, USA.). 
Clock Genes Analysis 
CLOCK and PER3 polymorphisms were detected by 
PCR and PCR-RFLP; and all tumor samples were 
processed for this study. 
1)  CLOCK Gene  
SNP T3111C (dbSNP ID: rs1801260) was detected 
by PCR amplification of a region of 221 bp, with 
subsequent digestion with Bsp 1286I, as described 
in Lattuada et al. (2004).  
2)  PER3 Gene 
PER3 length polymorphism (Accession No. 
AB047536) consists of 4 or 5 copies of a repeated 
sequence of 54 bp, located in exon 18. The detection 
of allelic variants was performed by PCR, using the 
primers forward 5'- TGGTCCCAGCAGTGAGAGT 
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-3' and reverse 5'-CCAGATGCTGCTCTACCTGAACC 
-3'. The reaction conditions were as follows; in a 
final volume of 15 μl: 1X buffer, 50 ng of DNA, 0.25 
mM of each primer, 200 μM dNTPs, 1.5 mM MgCl2, 
0.45 U of Taq Platinum Polymerase and H2O up to 
15 μl. PCR cycling consisted of an initial 
denaturation at 95°C for 5 min, followed by 30 
cycles at 95°C for 1 min, annealing at 57°C for 1 
min and elongation at 72°C for 1 min, with a final 
extension at 72°C for 5 min. The products (261 bp 
and 315 bp) were visualized in 2% agarose gels, 
stained with GelRed (Biotium Inc., CA, USA.). 
Statistical Methods 
Genotype and allele frequencies were calculated by 
simple gene counting. Population analyses (Hardy-
Weinberg and Linkage Disequilibrium) were carried 
out using the software Arlequin 3.5 (Excoffier and 
Lischer 2010). 
Results  
The present study evaluated the genotype distribution 
for the xenobiotic metabolizing enzymes GSTT1 and 
NAT2, and for the clock genes CLOCK and PER3, in 
65 breast tumor samples from argentinian women. 
Polymorphism analysis could be performed in 60 to 62 
samples, of the 65 available samples. Linkage 
disequilibrium analysis was performed only with 
samples in which genotypes were complete for all 
genes (55 samples). The results of genetic analysis are 
summarized in Tables I-III.  
TABLE I DISTRIBUTION OF CASES ACCORDING TO GSTT1, NAT2, CLOCK 
AND PER3 GENOTYPES 
Polymorphisms Cases N (%) 
GSTT1 
+/+; +/null 48 (80) 
null/null 12 (20) 
 
NAT2 
Wild-type homozygotes 3 (5) 
Heterozygotes 30 (49) 
Slow homozygotes 28 (46) 
 
CLOCK 
T/T 36 (58) 
T/C 25 (40) 
C/C 1 (2) 
 
PER3 
4/4 27 (44) 
4/5 27 (44) 
5/5 7 (12) 
Tumor samples were in Hardy-Weinberg equilibrium 
for all loci, except for GSTT1 due to the limitations of 
the detection technique. 
For GSTT1, 20% of the samples showed total absence 
of the gene (genotype null/null). When  NAT2 
genotypes were grouped by their associated acetylator 
phenotype, 5% of rapid acetylator phenotypes, 49% of 
intermediate phenotypes, and 46% of slow acetylator 
phenotypes were found. The frequency of the CLOCK 
homozygous T/T genotype was 58%, the heterozygous 
genotype T/C was 40% and the homozygous genotype 
C/C was 2%. The observed allele frequencies were T = 
0.78 and C = 0.22. In the case of PER3, 44% of the 
samples were homozygous 4/4, an equal percentage 
was heterozygous 4/5, and the remaining 12% was 
homozygous 5/5. Allele frequencies were 0.66 for the 
4-repeats allele and 0.34 for the 5-repeats allele (Tables 
I and II). Published allele frequencies for the genes 
under study are shown in Table II as reference.  
TABLE II OBSERVED ALLELE FREQUENCIES FOR GSTT1, NAT2, CLOCK 
AND PER3 IN BREAST TUMOR SAMPLES. PUBLISHED FREQUENCIES FOR 
OTHER POPULATIONS ARE PLACED AS REFERENCE 
Alleles 
Observed 
frequencies 
Published frequencies 
GSTT1 
null/
null 
0.200 0.110-0.212 
(Garte et al. 2001; 
Bailliet et al. 2007; 
Moore et al. 2004; 
Cotignola et al. 2013)1 
NAT2 
*4 0.295 0.226-0.512 
(Garte et al. 2001; 
Bailliet et al. 2007)2 
*5 0.303 0.250-0.460 
 *6 0.352 0.061-0.285 
*7 0.049 0.029-0.201 
CLOCK 
T 0.780 0.740-0.770 (Ciarleglio et al. 2008; 
Casiraghi et al. 2010)3 C 0.220 0.230-0.260 
PER3 
4 0.660 0.630-0.660 (Ciarleglio et al. 2008; 
Casiraghi et al. 2010)3 5 0.340 0.340-0.370 
1Published frequencies for Caucasians, native Amerindians from 
Argentina and Paraguay, and populations from Córdoba and 
Buenos Aires (Argentina) 
2 Published frequencies for Caucasians and native Amerindians 
from Argentina and Paraguay 
3 Published frequencies for European Americans and a population 
from Buenos Aires (Argentina) 
Linkage disequilibrium test performed by Arlequin 
software (Table III), between all loci in Hardy- 
Weinberg equilibrium, indicated evidence of strong 
linkage between NAT2 and CLOCK (χ2 = 13.076; p = 
0.005). 
TABLE III LINKAGE DISEQUILIBRIUM TEST. THE TABLE SHOWS Χ2, p AND 
DEGREES OF FREEDOM FOR EACH PAIR OF LOCI 
Pairs  
NAT2/CLOCK 
χ2 13.076 
p 0.005 
d.f. 3 
NAT2/PER3 
χ2 3.590 
p 0.309 
d.f. 3 
CLOCK/PER3 
χ2 0.110 
p 0.740 
d.f. 1 
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Discussion 
Numerous studies have demonstrated that 
environmental and estrogen-related exposures play a 
role in breast cancer etiology (Kocabas 2002). There is 
evidence that several polymorphisms in enzymes 
involved in the metabolism of endogenous and 
exogenous compounds, increase the risk of developing 
cancer (Dunning et al. 1999; Autrup 2000). Moreover, 
genetic variants in key genes of the circadian clock 
may also alter the individual cancer susceptibility, 
through the regulation of CCG involved in 
proliferation and cell cycle control. Under this 
hypothesis, a number of studies have investigated the 
association between clock genes polymorphisms and 
certain types of cancers (Zhu et al. 2005; Zhu et al. 2006; 
Zhu et al. 2008; Hoffman et al. 2010; Dai et al. 2011; 
Chu et al. 2008). 
Although the risk of breast cancer due to genetic 
alterations in the genes analized here may not be as 
intense as the risk due to high penetrance genes, such 
as BRCA1 and BRCA2, they affect a higher percentage 
of individuals, leading to a higher impact in the 
population as a whole (B. L. Weber and Nathanson 
2000). However, analyses done with mixed racial 
American population have exhibited conflicting results. 
GSTT1 deletion frequency varies among different 
populations (Garte et al. 2001). The prevalence of the 
GSTT1 null genotype is lower among Caucasians (10–
20%) compared with Asians (50–60%) (Nelson et al. 
1995). NAT2 slow acetylator phenotype prevalence 
also varies worldwide. It is estimated that it is present 
in 10-20% of Asians, 35% of African Americans, 65-
90% of individuals of Middle Eastern descent, and 
about 55% of whites (Ambrosone et al. 2011). At the 
present time, it is accepted that the association 
between polymorphisms of NATs and cancer 
susceptibility exists, but this relation is modest and 
generally involves genes of phase I and II 
simultaneously. 
Bailliet et al. (2007) determined genotype and allele 
frequencies of several XMG, in a sample of healthy 
individuals from 8 Native American populations from 
Argentina and Paraguay, identified as Amerindians. 
As regards NAT2, the allelic frequencies obtained 
differ from those reported by Bailliet et al., probably 
due to different ethnic origin of samples.  
In another study conducted in the province of 
Cordoba, Argentina, with the aim to analyze risk 
factors for bladder cancer, researchers detected 16% 
and 11% of GSTT1 deletion in cases and controls, 
respectively (Moore et al. 2004). Moreover, Cotignola 
et al. (2013) informed a 21,2% of GSTT1 deletion in 105 
patients from Buenos Aires, Argentina, diagnosed 
with prostate cancer. In our study, 20% of samples 
with complete absence of GSTT1 was found. Although 
this percentage is close to reported values for other 
populations in Argentina, and for Caucasians in 
general, it represents one of the highest frequencies 
reported for the deletion in populations with similar 
ethnic origins. 
Argentinian population is highly heterogeneous 
because of the ethnic admixture of people from 
Europe, Africa and the native Amerindians. This 
admixture is spread along the country, with 
predominance of certain groups depending on the 
region. This heterogeneity means that, at present, 
genetic contributions of Native Americans, Europeans 
and Africans to the general population vary between 
different regions (Motti et al. 2009). 
As in the case of XMG, clock genes also differ in their 
allelic frequencies between different populations in the 
world. Ciarleglio et al. (2008) conducted a large study 
with population samples of African Americans, 
European Americans, Chinese and Africans. Our 
results are highly similar to those reported for 
European Americans. Furthermore, for the allele of 4-
repeats of PER3, Nadkarni et al. (2005) showed that 
European populations and African Americans have 
intermediate allelic frequencies, between 0.6 and 0.7 
approximately. 
In another study conducted in Argentina, Casiraghi et 
al. (2010) compared two local populations, one of 
healthy individuals and the other in which people 
were affected by bipolar disorder. The frequencies 
obtained for the control group (n = 39) were 0.63 for 
the 4-repeats allele and 0.37 for the 5-repets allele of 
PER3, and 0.77 for T allele and 0.23 for C allele of 
CLOCK. The frequencies obtained in our samples 
from patients with breast cancer are consistent with 
those reported by Casiraghi et al., and in general, with 
those observed in large population groups. 
In summary, NAT2 allelic frequencies observed in this 
study were different from those reported in the 
literature; it is thought that it is related to ethnic causes. 
As regards GSTT1, CLOCK and PER3, the frequencies 
observed in our breast tumor samples were within the 
frequency ranges published, as shown in Table II. 
Stratifying the samples according to tumor or patient 
characteristics may be a strategy to find differences in 
gene frequencies that affect cancer development, 
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instead of analyzing the samples as a whole.  
The linkage disequilibrium test performed in this 
study indicated a strong linkage between NAT2 and 
CLOCK. Up to date, there are no scientific 
publications that evaluate the impact of allelic variants 
of circadian genes and XMG together in the context of 
tumor development. It may be interesting to test, in a 
larger sample, if certain loci are in linkage 
disequilibrium in the population under study. This 
would indicate that some allelic combinations occur 
more frequently than other in cancer patients, thus 
having an impact on cancer development. 
A key limitation to arrive at more meaningful 
conclusions in this study is the low number of samples 
analyzed. Future studies should include a greater 
number of cases and appropriate controls, in order to 
survey the impact of polymorphisms in cancer 
development. In addition, it will be required to 
incorporate patient information. 
Conclusions 
This work constitutes a first approximation to a 
combined study of polymorphisms in XMG and clock 
genes in breast cancer Argentinian patients. A 
potential role for polymorphisms in breast cancer risk, 
prognosis and response to treatment merits further 
investigation. The possibility to identify individuals at 
increased risk would provide a useful tool in the fields 
of public health and preventive medicine. Given the 
central role of the circadian clock mechanisms in cell 
proliferation, cell cycle regulation, and apoptosis, and 
also the importance of the xenobiotic metabolizing 
system in absorption, distribution, metabolism and 
elimination of carcinogen compounds, a large amount 
of human genetic polymorphisms in XMG and clock 
genes are under characterization; and some of them 
show a correlation with risk of cancer, while the others 
remain equivocal and demand more investigation. 
Analyses of other polymorphisms of clock genes and 
XMG, as well as of mRNA expression in tumor tissues 
involving a large number of individuals are being 
carried out in our laboratory. 
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